

SIDLEY AUSTIN LLP  
Thomas R. Califano (TX Bar No. 24122825)  
William E. Curtin (admitted *pro hac vice*)  
Anne G. Wallace (admitted *pro hac vice*)  
787 Seventh Avenue  
New York, NY 10019  
Telephone: (212) 839-5300  
Facsimile: (212) 839-5599  
Email: tom.califano@sidley.com  
wcurtin@sidley.com  
anne.wallace@sidley.com

SIDLEY AUSTIN LLP  
Charles M. Persons (TX Bar No. 24060413)  
2021 McKinney Avenue, Suite 2000  
Dallas, Texas 75201  
Telephone: (214) 981-3300  
Facsimile: (214) 981-3400  
Email: cpersons@sidley.com

*Attorneys for the Debtors  
and Debtors in Possession*

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**NOTICE OF PROPOSED FORM OF AVEXITIDE SALE ORDER**

**PLEASE TAKE NOTICE** that, on April 1, 2024, the debtors and debtors in possession in the above-captioned chapter 11 cases (the “Debtors”) filed the *Debtors’ Motion for Entry of an Order (I)(A) Approving the Bid Procedures; (B) Authorizing the Debtors to Select Sentyln Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser & Approving Bid Protections; (C) Approving the Bid Protections Relating to the Remaining Assets Stalking Horse Purchaser(s), if any; (D) Establishing Bid Deadlines, Auction(s), and Sale Hearing(s); (E) Approving the Form*

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor’s federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors’ service address is 2100 Ross Avenue, Dallas, Texas 75201.



248004024062500000000011

*and Manner of Sale Notice; (F) Approving Assignment and Assumption Procedures; (G) Approving the Form and Manner of Potential Assumption and Assignment Notice; (II)(A) Authorizing the Sale of the Assets Free and Clear; and (B) Approving the Assumption and Assignment of Designated Contracts; And (III) Granting Related Relief* [Docket No. 13] (the “Motion”).

**PLEASE TAKE FURTHER NOTICE** that, on April 5, 2024, the Court entered an order granting, in part, the Motion and approving the bid procedures (the “Bid Procedures”) annexed as Exhibit 1 to the order [Docket No. 94] (the “Bid Procedures Order”).<sup>2</sup>

**PLEASE TAKE FURTHER NOTICE** that, on April 15, 2024, the Debtors filed the *Notice of Filing of Revised Bidding Procedures* [Docket No. 119], which included the revised Bid Procedures attached thereto as Exhibit A.

**PLEASE TAKE FURTHER NOTICE** that, on June 12, 2024, the Debtors filed the *Revised Notice of Sale, Bid Procedures, Auction, and Sale Hearing* [Docket No. 331], which included revised dates and deadlines for the Bid Deadline, Auction, and Sale Hearing for the Avexitide Sale Transaction

**PLEASE TAKE FURTHER NOTICE** that, pursuant to the Bid Procedures, the Debtors conducted the Auction for the Avexitide Assets on June 17, 2024 at 12:00 p.m. (CT).<sup>3</sup>

**PLEASE TAKE FURTHER NOTICE** that, pursuant to the Bid Procedures Order, Amylyx Pharmaceuticals, Inc. (“Amylyx”) has been designated the Winning Bidder with a final

---

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Bid Procedures Order.

<sup>3</sup> Further information on the Debtors’ marketing and sale process can be found in the *Declaration of Craig D. Warznak in Support of the Debtors’ Motion for the Sale of the Avexitide Assets and Motion for Entry of the Final Order (I) Authorizing the Debtors to Use Cash Collateral; (II) Granting Adequate Protection to Prepetition Term Loan Secured Parties; and (III) Modifying the Automatic Stay (the “Warznak Declaration”)* [Docket No. 361].

bid during the Auction of a Base Price in the amount of \$35,100,000 *plus* the aggregate amount of Determined Cure Costs and Assumed Liabilities (as defined in the Avexitide Sale Order).

**PLEASE TAKE FURTHER NOTICE** that, pursuant to the Bid Procedures Order, Spruce Biosciences, Inc. (“Spruce”), has been designated the Backup Bidder with its bid during the Auction of a Base Price in the amount of \$35,000,000.

**PLEASE TAKE FURTHER NOTICE** that, on June 21, 2024, the Debtors filed the *Notice of Selection of Winning Bid* [Docket No. 350], and attached as Exhibit A was a certain asset purchase agreement between the Debtors and Amylyx (the “Avexitide APA”).

**PLEASE TAKE FURTHER NOTICE** that, Amylyx seeks to purchase the Avexitide Assets free and clear of liens, claims, encumbrances, and other interests (the “Avexitide Sale Transaction”) on the terms set forth in the Avexitide APA.

**PLEASE TAKE FURTHER NOTICE** that attached as Exhibit A is a form of proposed order (the “Avexitide Sale Order”) authorizing the Debtors and Amylyx to enter into Avexitide APA and consummate the Avexitide Sale Transaction on the terms of the Avexitide APA.

**PLEASE TAKE FURTHER NOTICE** that the Debtors will seek entry of the Avexitide Sale Order at a hearing scheduled for **June 26, 2024, at 1:30 p.m. (CT)** before the Honorable Stacey G.C. Jernigan, United States Bankruptcy Judge for the Bankruptcy Court for the Northern District of Texas, Courtroom 1, floor 14, 1100 Commerce Street, Dallas, TX 75242-1496.

**PLEASE TAKE FURTHER NOTICE** that copies of the Motion and the Bid Procedures Order, as well as all related exhibits, including the Avexitide APA and this Notice are available by: (i) visiting the website of the Debtors’ claims, noticing, and solicitation agent, Kurtzman Carson Consultants LLC (“KCC”) at: <http://www.kccllc.net/eiger> (the “Case Website”), (ii) (888) 733-1544 (Toll-Free) or (310) 751-2638 (International), and/or (iii) emailing

[https://kccllc.net/eiger/inquiry](https://kccllc.net/eiger/inquiry;); or (iv) for a fee via PACER by visiting  
<http://ecf.txnb.uscourts.gov/>.

**PLEASE TAKE FURTHER NOTICE** that you may obtain additional information  
concerning these Chapter 11 Cases on the Case Website.

*[Remainder of page intentionally left blank]*

Dated: June 25, 2024  
Dallas, Texas

**SIDLEY AUSTIN LLP**

*/s/ Thomas R. Califano*

---

Thomas R. Califano (TX Bar No. 24122825)  
William E. Curtin (admitted *pro hac vice*)  
Anne G. Wallice (admitted *pro hac vice*)  
787 Seventh Avenue  
New York, NY 10019  
Telephone: (212) 839-5300  
Facsimile: (212) 839-5599  
Email: tom.califano@sidley.com  
wcurtin@sidley.com  
anne.wallice@sidley.com

*and*

Charles M. Persons (TX Bar No. 24060413)  
2021 McKinney Avenue, Suite 2000  
Dallas, Texas 75201  
Telephone: (214) 981-3300  
Facsimile: (214) 981-3400  
Email: cpersons@sidley.com

*Attorneys for the Debtors and Debtors in Possession*

**Certificate of Service**

I certify that on June 25, 2024, I caused a copy of the foregoing document to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Northern District of Texas.

/s/ Thomas R. Califano  
Thomas R. Califano

**Exhibit A**

**Avexitide Sale Order**

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**ORDER (I) APPROVING THE SALE  
OF THE DEBTORS' AVEXITIDE ASSETS,  
(II) AUTHORIZING ASSUMPTION AND ASSIGNMENT  
OF CERTAIN EXECUTORY CONTRACTS AND UNEXPIRED  
LEASES RELATED THERETO, AND (III) GRANTING RELATED RELIEF**

---

---

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Avenue, Dallas, Texas 75201.



Upon consideration of the Motion<sup>2</sup> of the debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the “Debtors”) for entry of an order (this “Avexitide Sale Order”), pursuant to sections 105(a), 363, and 365 of title 11 of the United States Code (the “Bankruptcy Code”) and Rules 2002, 6004, and 9014 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), Rule 9013-1 of the Bankruptcy Local Rules for the Northern District of Texas (the “Bankruptcy Local Rules”), and Section E of the *Procedures for Complex Chapter 11 Cases in the Northern District of Texas* (the “Complex Case Procedures”), authorizing (a) the Debtors’ sale of certain of their property free and clear of liens, claims, encumbrances, and interests on the terms set forth in that certain *Asset Purchase Agreement by and between Amylyx Pharmaceuticals, Inc., or a wholly owned subsidiary thereof, as Purchaser, and Eiger BioPharmaceuticals, Inc., as Seller, Dated as of June 21, 2024*, (the “Avexitide APA”) [Docket No. 350, Ex. A]; (b) the assumption and assignment of the Designated Contracts in connection with the Avexitide APA;<sup>3</sup> and (c) granting related relief, all as more fully set forth in the Motion; and this Court having previously entered the *Order (I)(A) Approving the Bid Procedures; (B) Authorizing the Debtors to Select Sentynl Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser & Approving Bid Protections; (C) Approving the Bid Protections Relating to the Remaining Assets Stalking Horse Purchaser(s), if any; (D) Establishing Bid*

---

<sup>2</sup> Capitalized terms used by not otherwise defined herein shall have the meanings ascribed to such terms in the *Debtors’ Motion for Entry of an Order (I)(A) Approving the Bid Procedures; (B) Authorizing the Debtors to Select Sentynl Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser & Approving Bid Protections; (C) Approving the Bid Protections Relating to the Remaining Assets Stalking Horse Purchaser(s), if any; (D) Establishing Bid Deadlines, Auction(s), and Sale Hearing(s); (E) Approving the Form and Manner of Sale Notice; (F) Approving Assignment and Assumption Procedures; (G) Approving the Form and Manner of Potential Assumption and Assignment Notice; (II)(A) Authorizing the Sale of the Assets Free and Clear; and (B) Approving the Assumption and Assignment of Designated Contracts; And (III) Granting Related Relief* [Docket No. 13] (the “Motion”) or the Avexitide APA.

<sup>3</sup> The terms “Designated Contracts” and “Assigned Contracts” as used herein shall have the meanings ascribed to them in the Avexitide APA.

*Deadlines, Auction(s), and Sale Hearing(s); (E) Approving the Form and Manner of Sale Notice; (F) Approving Assignment and Assumption Procedures; (G) Approving the Form and Manner of Potential Assumption and Assignment Notice; (II)(A) Authorizing the Sale of the Assets Free and Clear; and (B) Approving the Assumption and Assignment of Designated Contracts; And (III) Granting Related Relief* [Docket No. 94] (the “Bid Procedures Order”); and the Debtors having filed the *Notice of Selection of Winning Bid* [Docket No. 350] (the “Notice of Winning Bid”), pursuant to the Bid Procedures Order, and selected Amylyx Pharmaceuticals, Inc. (“Amylyx”) as the highest or otherwise best bidder for the Transferred Assets (the “Purchaser”) pursuant to the Avexitide APA following the Auction and the Purchaser having submitted the highest or otherwise best offer for assets to be sold to the Purchaser as identified in the Avexitide APA (the “Transferred Assets”), as reflected in the Avexitide APA and as from time to time may be amended in accordance with this Avexitide Sale Order or further order of this Court, including by the Avexitide APA, pursuant to which the Debtors have agreed, among other things, to sell the Transferred Assets to the Purchaser, including the Assigned Contracts that will be assumed and assigned to the Purchaser on the terms and conditions set forth in the Avexitide APA inclusive of the Avexitide Purchase Price (as defined below) (collectively, the “Avexitide Sale Transaction”); and the Debtors having filed the *Notice of Cure Amounts and Potential Assumption and Assignment of Executory Contracts and Unexpired Leases in Connection with the Remaining Sale Transaction* [Docket No. 313] (the “Cure Notice”) and served the *Designated Contracts and Cure Amounts* [Docket No. 350, Ex. B] (the “Assignment Notice”) in accordance with the Bid Procedures Order; and this Court having conducted the hearing to consider approval of the Avexitide Sale Transaction (the “Avexitide Sale Hearing”), at which time all interested parties were offered an opportunity to be heard with respect to the Avexitide Sale Transaction; and this

Court having reviewed and considered (i) the Motion and the exhibits thereto, (ii) the First Day Declaration [Docket No. 27], (iii) and the *Declaration of Craig D. Warznak in Support of the Debtors' Motion for the Sale of the Avexitide Assets and Motion for Entry of the Final Order (I) Authorizing the Debtors to Use Cash Collateral; (II) Granting Adequate Protection to Prepetition Term Loan Secured Parties; and (III) Modifying the Automatic Stay* [Docket No. 361], and the arguments and representations of counsel made, and the evidence proffered or adduced at the Avexitide Sale Hearing; and it appearing that due and proper notice of the Motion, the Avexitide APA, the Cure Notice, the Assignment Notice, the Bid Procedures Order, and this Avexitide Sale Order having been provided in accordance with the Bid Procedures Order; and all objections, if any, to approval of the Avexitide Sale Transaction having been withdrawn, resolved (including by separate agreement between the objecting party and the Debtors), adjourned, or overruled as provided in this Avexitide Sale Order; and it appearing entry of this Avexitide Sale Order and consummation of the Avexitide Sale Transaction are in the best interests of the Debtors, their estates and creditors, and all parties in interest in these chapter 11 cases; and upon the record of the Avexitide Sale Hearing and these chapter 11 cases; and after due deliberation thereon; and sufficient cause appearing therefor,

**IT IS HEREBY FOUND AND DETERMINED THAT:**

A. **Fed. R. Bankr. P. 7052.** The findings and conclusions set forth herein constitute this Court's findings of fact and conclusions of law pursuant to Bankruptcy Rule 7052, made applicable to this proceeding pursuant to Bankruptcy Rule 9014. To the extent any of the following findings of fact constitute conclusions of law, they are adopted as such. To the extent any of the following conclusions of law constitute findings of fact, they are adopted as such. This Court's findings shall also include any oral findings of fact and conclusions of law made by this Court

during or at the conclusion of the Avexitide Sale Hearing. To the extent of any conflict, the oral rulings control.

B. **Jurisdiction and Venue.** This Court has jurisdiction over the Motion and the Avexitide Sale Transaction described therein, and in the Avexitide APA, including, without limitation, the sale of the Transferred Assets, pursuant to 28 U.S.C. §§ 157 and 1334. Venue for these Chapter 11 Cases is proper pursuant to 28 U.S.C. § 1408. This Court may enter a final order consistent with Article III of the United States Constitution. This is a core proceeding pursuant to 28 U.S.C. § 157(b).

C. **Statutory Predicates.** The statutory authorization for the relief granted herein is found in sections 105(a), 363, and 365 of the Bankruptcy Code; Bankruptcy Rules 2002, 6004, and 9014; Rule 9013-1 of the Bankruptcy Local Rules; and Section E of the Complex Case Procedures.

D. This Avexitide Sale Order constitutes a final and appealable order within the meaning of 28 U.S.C. § 158(a). Time is of the essence in closing the Avexitide Sale Transaction referenced herein, and the Debtors and the Purchaser intend to close the Avexitide Sale Transaction as soon as practicable in accordance with the Avexitide APA, and there is no just reason for delay in the implementation of this Avexitide Sale Order. Specifically, the Avexitide Sale Transaction must be approved and consummated promptly in accordance with the Avexitide APA to preserve the viability of the business in the hands of the Purchaser as a going concern, and to maximize the value to the Debtors, their estates, their creditors, and all other parties in interest. Notwithstanding Bankruptcy Rules 6004(h) and 6006(d), and to any extent necessary under Bankruptcy Rule 9014 and Rule 54(b) of the Federal Rules of Civil Procedure, as made applicable by Bankruptcy Rule 7054, the Court expressly finds that there is no just reason for delay in the implementation of this

Avexitide Sale Order in accordance with the Avexitide APA, waives any stay, and expressly directs entry of judgment as set forth herein.

E. **Incorporation By Reference.** Findings of fact and conclusions of law in the Bid Procedures Order are incorporated herein by reference.

F. **Marketing Process & Auction.** The Debtors and their professionals adequately marketed the Transferred Assets to all Potential Bidders in accordance with the Bid Procedures Order. The sale process set forth in the Bid Procedures Order afforded all Potential Bidders (as defined in the Bid Procedures, attached as Exhibit 1 to the Bid Procedures Order and revised in that *Notice of Filing of Revised Bidding Procedures*, filed on April 15, 2024 [Docket No. 119]) a full, fair, and reasonable opportunity to submit a higher or otherwise better offer to purchase the Transferred Assets and participate in the sale process. The Auction was conducted in a reasonable and fair manner in accordance with the Bid Procedures. No other person, or group of persons, has offered to purchase the Transferred Assets for an amount that would give greater value to the Debtors than the value provided by the Purchaser pursuant to the Avexitide APA, which reflects the final bid during the Auction of a Base Price in the amount of \$35,100,000 *plus* the aggregate amount of Determined Cure Costs and Assumed Liabilities (the “Avexitide Purchase Price”). The Avexitide Purchase Price constitutes the highest and best bid for the Transferred Assets. The marketing process was robust and sufficiently tested the market to determine the highest and best offer for the Transferred Assets.

G. **Sale Hearing.** This Court conducted the Avexitide Sale Hearing on June 26, 2024, at which time this Court considered the Motion, the evidence and testimony presented, and the statements and argument of counsel, as applicable, in support of the Motion, the Avexitide APA, and the Avexitide Sale Transaction. Except as otherwise expressly provided in this Avexitide Sale

Order, all objections to the Avexitide Sale Transaction and the relief requested in the Motion, whether timely or untimely and whether written or made orally at the Avexitide Sale Hearing, if any, were heard and considered by this Court. All such objections, if any, were either overruled by this Court, are resolved by the terms hereof or by separate agreement between the objecting party and the Debtors, or were adjourned or withdrawn as a result of an agreement between the objecting party and the Debtors.

H. **Sound Business Purpose.** The Debtors have demonstrated good, sufficient, and sound business purposes and justifications for consummation of the Avexitide Sale Transaction pursuant to the Avexitide APA and all other agreements, instruments, certificates, and other documents to be entered into or delivered by any party in connection with the Avexitide Sale Transaction, including, without limitation, any assumption and assignment agreements entered into in connection therewith (collectively, the “Transaction Documents”), outside of the ordinary course of business and in accordance with the requirements of section 363(b) of the Bankruptcy Code. Consummation of the Avexitide Sale Transaction prior to and not as part of a chapter 11 plan is (i) justified under the circumstances, (ii) an appropriate exercise of the Debtors’ business judgment, and (iii) in the best interests of the Debtors, their estates, and their creditors.

I. Following a robust marketing process and Auction consistent with the Bid Procedures Order, the Avexitide APA and the Avexitide Purchase Price constitute the highest or otherwise best offer for the Transferred Assets. No other person, or group of persons, has offered to purchase the Transferred Assets for an amount that would give greater value to the Debtors than the value provided by the Avexitide Purchase Price. The Avexitide Sale Transaction is the best means available to the Debtors to maximize the return to their creditors and limit the losses to

counterparties to the Assigned Contracts. No alternative to the Avexitide Sale Transaction exists that would provide a greater value to the Debtors, their creditors, or other parties in interest.

J. Approval of the Avexitide Sale Transaction is necessary to maximize the value the Debtors' estates will receive for the Transferred Assets. It is important to the Debtors' customers and suppliers that the transition from the Debtors to the Purchaser occurs smoothly and without unnecessary delay, so that any customer and vendor issues may be minimized. It is also important that the Avexitide Sale Transaction be consummated as expeditiously as possible to avoid any disruption to the ongoing development of Avexitide and so there is no uncertainty about the future of the Avexitide Assets.

K. Accordingly, the sale of the Transferred Assets pursuant to sections 105(a), 363, and 365 of the Bankruptcy Code upon the terms and conditions set forth in the Avexitide APA is the optimal means to create value for the benefit of the Debtors' estates. The Avexitide Sale Transaction maximizes the value of the Transferred Assets because the Transferred Assets are being sold as part of a going concern, thereby preserving the continuity and remaining goodwill value associated with the Transferred Assets. Unless the sale is concluded expeditiously, as provided for in the Motion and the Avexitide APA, creditor recoveries may be substantially diminished.

L. **Fair Purchase Price.** The Avexitide Purchase Price provided by the Purchaser as set at the Auction (i) is fair and adequate; (ii) constitutes reasonably equivalent value and fair consideration under the Bankruptcy Code and under the laws of the United States, any state, territory, possession, or the District of Columbia (including the Uniform Fraudulent Transfer Act, the Uniform Fraudulent Conveyance Act, and similar laws); and (iii) will provide an equal or greater recovery for the Debtors' creditors than would be provided by any other available

alternative. The terms of the Avexitide APA, the Transaction Documents, and the Avexitide Sale Transaction are fair and reasonable under the circumstances of the Debtors' chapter 11 cases, and the Debtors' determination to proceed with such transaction constitutes a valid and sound exercise of the Debtors' business judgment.

M. **Adequate and Reasonable Notice**. As evidenced by the affidavits of service filed with this Court [Docket Nos. 42, 114, 128, 140, 319, 320, 324, 362], and based upon the record of the Avexitide Sale Hearing, and as previously determined by this Court in the Bid Procedures Order, (i) due, proper, timely, adequate, and sufficient notice of the Motion, the Avexitide Auction, the Avexitide Sale Hearing, the Avexitide APA, and the Avexitide Sale Transaction has been provided to all parties in interest, (ii) such notice was and is good, sufficient, and appropriate under the circumstances, and reasonably calculated to reach and apprise all holders of Liens, claims, encumbrances, and other Interests (as defined herein), including, without limitation, rights or claims based on any successor, transferee, derivative, or vicarious liabilities, and was provided in accordance with the applicable requirements of the Bankruptcy Code, the Bankruptcy Rules, the Bankruptcy Local Rules, the Complex Case Procedures, and the procedural due process requirements of the United States Constitution, and (iii) no other or further notice of the Motion, the Avexitide Auction, the Avexitide Sale Hearing, the Avexitide APA, the Avexitide Sale Transaction, or of the entry of this Avexitide Sale Order is necessary or shall be required.

N. In accordance with the Bid Procedures Order, the Debtors filed with this Court and served the Cure Notice, containing (i) the list of all Designated Contracts to potentially be assigned in connection with the Avexitide Sale Transaction, (ii) information necessary and appropriate to provide notice of the relevant proposed assumption and assignment of Potentially Assigned Contracts (as defined in the Cure Notice) and rights thereunder, (iii) Cure Amounts, where



applicable, and (iv) the procedures for objecting thereto, on all counterparties to such Potentially Assigned Contracts and any party that has requested notice pursuant to Bankruptcy Rule 2002 (“Rule 2002 Notice List”), and caused such notice to be published on the website of the Debtors’ noticing agent, Kurtzman Carson Consultants LLC (“KCC”) [Docket No. 313]. The Cure Notice (a) included the Debtors’ good faith calculation of the Cure Amounts with respect to each Potentially Assigned Contract; (b) stated that assumption or assignment of any Potentially Assigned Contract is not guaranteed and is subject to this Court’s approval; (c) prominently displayed the deadline to file a Cure Objection (as defined herein); and (d) prominently displayed the dates, times, and location of the Avexitide Sale Hearing. The service and provision of the Cure Notice was good, sufficient, and appropriate under the circumstances, and no other or further notice need be given.

O. In accordance with the Bid Procedures Order, the Debtors also served the Assignment Notices on the counterparties to the Designated Contracts, which contained (i) the list of Designated Contracts selected by the Purchaser, (ii) information necessary and appropriate to provide notice of the relevant proposed assumption and assignment of the Designated Contracts and rights thereunder, (iii) the Cure Amounts, and (iv) the procedures for objecting thereto, on all counterparties to the Designated Contracts and all parties on the Rule 2002 Notice List. The service and provision of the Notice of Designated Contracts was good, sufficient, and appropriate under the circumstances, and no other or further notice need be given in connection with the assumption and assignment of the Designated Contracts.

P. A reasonable opportunity to object and to be heard with respect to the sale of the Transferred Assets, the assumption and assignment of the Designated Contracts, and the

determination of defaults and Cure Amounts related thereto, as well as the Avexitide APA and the entry of this Avexitide Sale Order, has been given to all interested Persons.

Q. **Good Faith Purchaser.** The Debtors, the Purchaser, and their respective principals, counsel, and advisors have negotiated, proposed, and entered into the Avexitide APA, the Transaction Documents, and each of the transactions contemplated therein in good faith, without collusion and from arm's-length bargaining positions. The Purchaser is a "good faith purchaser" and is acting in good faith within the meaning of section 363(m) of the Bankruptcy Code in connection with the Avexitide Sale Transaction and, as such, is entitled to all the protections afforded thereby. The Purchaser has proceeded in good faith in all respects. The terms of the Avexitide Sale Transaction, including the Avexitide Purchase Price, were not controlled by any agreement among Potential Bidders and neither the Debtors nor the Purchaser have engaged in collusion or any conduct that would cause or permit the Avexitide APA to be challenged, avoided or costs and damages to be imposed under section 363(n) of the Bankruptcy Code or any other law of the United States, any state, territory, possession thereof, or the District of Columbia, or any other applicable law. The Avexitide APA was not entered into for the purpose of hindering, delaying, or defrauding creditors under the Bankruptcy Code or under laws of the United States, any state, territory, or possession, or the District of Columbia, or any other applicable law. Neither the Debtors nor the Purchaser entered into the Avexitide APA or are consummating the Avexitide Sale Transaction with any fraudulent or otherwise improper purpose. The Purchaser is not an "insider" or "affiliate" of any of the Debtors, as those terms are defined in section 101 of the Bankruptcy Code, and no common identity of incorporators, directors, or controlling stockholders exists between the Purchaser and the Debtors.

R. The Avexitide Sale Transaction, which includes the sale of the Transferred Assets pursuant to the Avexitide APA and all covenants in and conditions thereto, is an integrated transaction, meaning that each component is an essential part of every other component and that the Avexitide Sale Transaction can be consummated only if all of the components are consummated. Accordingly, each component of the Avexitide Sale Transaction is subject to, and is protected by, the provisions of section 363(m) of the Bankruptcy Code.

S. **Sale Free and Clear under Section 363(f)**. The Purchaser would not have entered into the Avexitide APA and would not consummate the Avexitide Sale Transaction without entry of this Avexitide Sale Order approving the Avexitide Sale Transaction pursuant to section 363(f) of the Bankruptcy Code. Except as expressly provided otherwise in the Avexitide APA or this Avexitide Sale Order, the Debtors have satisfied the standard set forth in section 363(f) of the Bankruptcy Code for selling the Transferred Assets free and clear of all of the following (collectively, “Interests”): Liens (including Permitted Liens), claims (including, but not limited to, those that constitute a “claim” as defined in section 101(5) of the Bankruptcy Code), encumbrances, obligations, liabilities, pledges, charges, demands, guarantees, actions, suits, defenses, deposits, credits, allowances, options, rights, restrictions, limitations, contractual commitments, rights of first refusal, rights of setoff or recoupment, royalties, hypothecations, preferences, debts, easements, suits, licenses, rights of recovery, judgments, orders and decrees of any court or foreign or domestic governmental entity, taxes (including foreign, state, and local taxes), covenants, indentures, instruments, leases, claims for reimbursement or subrogation, contribution, indemnity or exoneration, encumbrances, or interests of any kind or nature whatsoever against the Debtors, or any of the Transferred Assets, including, without limitation, any debts arising under or out of, in connection with, or in any way relating to, any acts or

omissions, obligations, demands, guaranties, rights, contractual commitments, restrictions, product liability claims, environmental liabilities, employment or labor law claims or liabilities, employee pension or benefit plan claims, multiemployer benefit plan claims, retiree healthcare or life insurance claims or claims for taxes of or against the Debtors or against any property of the Debtors, claims arising under state or federal antitrust laws, any indemnification claim or liabilities relating to any act or omission of the Debtors or any other person prior to the Closing Date or any Excluded Liabilities, any derivative, vicarious, transferee or successor liability claims, alter ego claims, de facto merger claims, rights or causes of action (whether known or unknown, legal or equitable, contingent, matured or unmatured, contingent or non-contingent, liquidated or unliquidated, choate or inchoate, filed or unfiled, scheduled or unscheduled, perfected or unperfected, allowed or disallowed, noticed or unnoticed, recorded or unrecorded, material or non-material, statutory or non-statutory, and asserted or unasserted), whether arising prior to or subsequent to the commencement of the Debtors' chapter 11 cases (other than the Assumed Liabilities), whether imposed by agreement, understanding, law, equity or otherwise, including without limitation (i) those Interests that purport to give to any party a right or option to effect a setoff against or any forfeiture, modification, or termination of the Debtors' interests in the Transferred Assets, or any similar rights, if any, (ii) those Interests arising under all mortgages, deeds of trust, security interests, conditional sale or other title retention agreements, pledges, hypothecations, liens, judgments, demands, encumbrances, rights of first refusal or charges of any land or nature, if any, (iii) those Interests that are Excluded Liabilities as set forth in the Avexitide APA, (iv) those Interests held by the Prepetition Term Loan Lenders (as defined in the Final Cash Collateral Order) as provided in the order entered by the Court at Docket No. 161 (the "Final Cash Collateral Order"), and (v) those Interests arising under or out of, in connection with, or in any

way related to the Debtors or any of the Debtors' predecessors, Affiliates, or representatives, any of the Debtors' interests in the Transferred Assets, or the operation of any of the Debtors' businesses before the applicable Closing Date, including, without limitation, Interests based on successor liability, transferee liability, derivative liability, vicarious liability, de facto merger, continuation or continuity, or any similar theories under applicable state or federal law or otherwise. Each holder of an Interest in the Transferred Assets (a) has, subject to the terms and conditions of this Avexitide Sale Order, consented or shall be deemed to have consented to the relief requested in the Motion and with respect to the Avexitide Sale Transaction, (b) could be compelled in a legal or equitable proceeding to accept money satisfaction of such Interest, or (c) otherwise falls within the provisions of section 363(f) of the Bankruptcy Code. Those holders of Interests that did not object to, or withdrew their objections, if any, to, the relief requested in the Motion, the Avexitide APA, the Avexitide Sale Transaction, or the Assignment Notices are deemed to have consented to the relief requested in the Motion, including, without limitation, the sale of the Transferred Assets and the assumption and assignment of the Assigned Contracts to the Purchaser, pursuant to section 363(f)(2) of the Bankruptcy Code. Those holders of Interests that did object that have an Interest in the Transferred Assets could be compelled in a legal or equitable proceeding to accept money satisfaction of such Interest pursuant to section 363(f)(5) of the Bankruptcy Code or fall within one or more of the other subsections of 363(f) of the Bankruptcy Code and, therefore, are adequately protected by having their Interests that constitute interests in the Transferred Assets, if any, attach solely to the proceeds of the Avexitide Sale Transaction ultimately attributable to the property in which they have an Interest, in the same order of priority and with the same validity, force, and effect that such holders had prior to the Avexitide Sale Transaction, subject to any defenses of the Debtors.

T. Except as expressly provided otherwise in the Avexitide APA or this Avexitide Sale Order, neither the Purchaser nor any of the Purchasers' Affiliates (including any subsidiary of the Purchaser, any person or entity that could be treated as a single employer with the Purchaser pursuant to Section 4001(b) of the Employee Retirement Income Security Act of 1974, as amended ("ERISA") or Section 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended ("IRC"), and any of their respective managed funds or accounts, any of their respective lenders or investors, and, in each case of the foregoing, each of their respective former, current, or future, shareholders, equity holders, owners, members, managers, employees, representatives, officers, limited or general partners, directors, agents, professionals, successors, affiliates, or permitted assignees) (collectively with the Purchaser, the "Purchaser Group") shall be responsible for any Interests, including in respect of, based on, relating to, or arising under, without limitation, the following: (i) any labor, collective bargaining, or employment agreements; (ii) any mortgages, deeds of trust, or security interests; (iii) any intercompany loans and receivables between one or more of the Seller and any Debtor; (iv) any pension, multiemployer (as such term is defined in Section 3(37) or Section 4001(a)(3) of ERISA), health or welfare plan participation or benefit trust, compensation or other employee benefit plans, agreements, practices and programs (including any Employee Benefit Plan) of or related to any of the Debtors or any of the Debtors' Affiliates or predecessors or any current or former employees of any of the foregoing, including, without limitation, any pension plan of any of the Debtors or any multiemployer plan to which the Debtors have at any time contributed to or had any liability or potential liability; (v) the Debtors' business operations or cessation thereof; (vi) any litigation involving one or more of the Debtors; (vii) any other employee, worker's compensation, occupational disease or unemployment or temporary disability related claim, including, without limitation, claims that might otherwise arise under or

pursuant to (a) ERISA, (b) the Fair Labor Standards Act, (c) Title VII of the Civil Rights Act of 1964, (d) the Federal Rehabilitation Act of 1973, (e) the Multi-Employer Pension Plan Amendments Act of 1980, including all amendments thereto, (f) the Worker Adjustment and Retraining Notification Act of 1988 or any similar state or local law (“WARN”), (g) the Americans with Disabilities Act of 1990, (h) the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, including, without limitation, the requirements of Part 6 of Subtitle B of Title I of ERISA and Section 4980B of the IRC and of any similar state law (collectively, “COBRA”), (i) the National Labor Relations Act, (j) the Age Discrimination and Employment Act of 1967 and Age Discrimination in Employment Act, as amended, (k) state harassment, discrimination, or retaliation laws, (l) state unemployment compensation laws or any other similar state laws, or (m) any other state or federal benefits or claims relating to any employment with the Debtors or any of their predecessors, or relating to any wages, benefits, employment, or termination of employment with any or all Debtors or any of their predecessors; (viii) any liabilities arising under any Environmental Laws with respect to any assets owned or operated by any of the Debtors or any corporate predecessor of any of the Debtors at any time prior to the applicable Closing Date; (ix) any product liability law; (x) any antitrust laws; (xi) any bulk sales or similar law; (xii) any tax statutes or ordinances, including, without limitation, the IRC; and (xiii) any Excluded Liabilities.

U. **No Successor, Transferee, or Similar Liability.** Except for the Assumed Liabilities, as expressly set forth in the Avexitide APA or this Avexitide Sale Order, the Purchaser has not expressly or impliedly assumed any obligation of the Debtors, or any other party, with respect to the Interests and the Excluded Liabilities, whether at law or in equity, whether by payment, setoff, recoupment, or otherwise, directly or indirectly, and whether from the Transferred

Assets or otherwise, including, without limitation, based on successor, transferee, derivative, or vicarious liability.

V. The Avexitide Sale Transaction described by the Avexitide APA and the Transaction Documents does not amount to a consolidation, merger, or de facto merger of the Purchaser and any of the Debtors and/or any of the Debtors' estates.

W. There is no continuity between the Purchaser and any of the Debtors. The Purchaser is not holding itself out to the public as a continuation of any of the Debtors or their respective estates, businesses, or operations. The Purchaser is not a mere continuation of any of the Debtors or their respective estates, businesses, or operations. There is no common identity between any of the Debtors and the Purchaser. The Purchaser does not constitute a successor or a successor in interest to any of the Debtors or their estates.

X. The Purchaser and the Debtors are not entering into the Avexitide APA and Transaction Documents or consummating the Avexitide Sale Transaction for the fraudulent purpose of escaping liability for the Debtors' obligations or to defraud creditors in any way.

Y. **Sale Free and Clear and Continuation of Existing Approvals Required by the Purchaser.** The Purchaser expressly negotiated for the protection of obtaining the Transferred Assets free and clear of all Interests, including, without limitation, any potential successor liability claims (other than the Assumed Liabilities). The total consideration to be provided under the Avexitide APA reflects the Purchaser's reliance on this Avexitide Sale Order to provide it, pursuant to sections 105(a), 363, and 365 of the Bankruptcy Code, with title to and possession of the Transferred Assets free and clear of all Interests of any kind or nature whatsoever (including, without limitation, any potential successor liability claims (other than the Assumed Liabilities))). The Purchaser would not have entered into the Avexitide APA and would not



consummate the Avexitide Sale Transaction if the sale of the Transferred Assets to the Purchaser and the assumption and assignment of the Assigned Contracts to the Purchaser by the Debtors were not free and clear of all Interests of any kind or nature whatsoever (other than the Assumed Liabilities), as contemplated by this Avexitide Sale Order, or if the Purchaser would, or in the future could, be liable for any of the Interests, including, without limitation, rights or claims based on any successor, transferee, derivative, or vicarious liabilities. The Purchaser would not have entered into the Avexitide APA and would not consummate the Avexitide Sale Transaction if the Purchaser would not be authorized, as of the Closing Date, to operate under or renew any license, permit, registration, and governmental authorization or approval of the Debtors with respect to the Transferred Assets (subject, in each case, to the terms and conditions of the Avexitide APA); if such licenses, permits, registrations, and governmental authorizations or approvals would not be deemed to have been transferred to the Purchaser as of the Closing Date; or if existing licenses or permits applicable to the business would not remain active and in place for the Purchaser's benefit until either new licenses and permits are obtained or existing licenses and permits are transferred.

Z. **Assumption and Assignment of the Designated Contracts.** The Assumption and Assignment Procedures approved pursuant to the Bid Procedures Order are integral to the Avexitide APA, do not constitute unfair discrimination, are in the best interests of the Debtors, their estates and creditors, and all other parties in interest, and are based on the reasonable exercise of sound business judgment by the Debtors. At the Closing and pursuant to Section 365 of the Bankruptcy Code and this Avexitide Sale Order, the Debtors shall assume and, subject to the terms in the Avexitide APA, assign to the Purchaser, and Purchaser shall take assignment from the Debtors of, the Assigned Contracts.

AA. On or after the Closing Date, the Purchaser will pay all Cure Amounts with respect to the Designated Contracts proposed to be resolved after the Closing Date in accordance with Paragraph 20 below. Accordingly, the Debtors or the Purchaser, as applicable, will have, to the extent necessary, (i) cured any default existing prior to the Closing with respect to the Designated Contracts, and (ii) provided compensation, if any, to each counterparty to a Designated Contract for any actual pecuniary loss to such party resulting from a default prior to the Closing with respect to the Designated Contract with such counterparty, all within the meaning of sections 365(b)(1)(A) and 365(f)(2)(A) of the Bankruptcy Code.

BB. Pursuant to section 365(f) of the Bankruptcy Code, each Assigned Contract required to be assumed and assigned under the Avexitide APA shall be assigned and transferred to, and remain in full force and effect for the benefit of, the Purchaser, in accordance with their respective terms, notwithstanding any provision in such contract or other restrictions prohibiting its assignment or transfer. No section of any of the Assigned Contracts that would directly or indirectly prohibit, restrict, or condition the assumption or assignment of any of the Assigned Contracts or would permit termination or modification of such Assigned Contracts, or rights and obligations thereunder, by a party other than the Debtors, on account of assignment of such shall have any force or effect in connection with the Transferred Assets.

CC. The assumption and assignment of the Assigned Contracts (i) are necessary to sell the Transferred Assets to the Purchaser, (ii) allow the Debtors to sell the Transferred Assets to the Purchaser as a going concern, (iii) limit the losses suffered by counterparties to the Assigned Contracts, and (iv) maximize the recoveries to other creditors of the Debtors by limiting the number of claims against the Debtors' estates by avoiding the rejection of the Assigned Contracts. For these reasons, the Debtors have exercised sound business judgment in assuming

and assigning the Assigned Contracts and such assumption and assignment is in the best interests of the Debtors' estates.

DD. **Adequate Assurance of Future Performance.** Counterparties to the Designated Contracts were provided with the Assignment Notice and had the opportunity to request and review information with respect to the Purchaser's adequate assurance of future performance (*see* Docket No. 94, Ex. 5) and were required to file any objections to the Purchaser's ability to provide adequate assurance of future performance as contemplated under sections 365(b)(1)(C), 365(b)(3) (to the extent applicable) and 365(f)(1) of the Bankruptcy Code (each, a "Cure Objection") on or prior to June 12, 2024 at 4:00 P.M. Central Time. Counterparties to Designated Contracts that failed to timely file a Cure Objection are hereby forever barred from objecting to the assumption and assignment of Designated Contracts on the grounds of a failure to provide adequate assurance of future performance. Based on evidence adduced at the Avexitide Sale Hearing and based on the record in these chapter 11 cases, to the extent necessary, the Debtors have satisfied the requirements of section 365 of the Bankruptcy Code, including sections 365(b)(1)(A), 365(b)(1)(B), 365(b)(1)(C), 365(b)(3) (to the extent applicable) and 365(f) of the Bankruptcy Code, in connection with the sale and assumption and assignment of the Assigned Contracts to the extent provided under the Avexitide APA. Accordingly, subject to payment of the Cure Amounts, the Assigned Contracts may be assumed by the Debtors and assigned to the Purchaser as provided under the Avexitide APA and this Avexitide Sale Order.

EE. **Sale Order Required by the Purchaser.** Entry of this Avexitide Sale Order approving the Avexitide APA is a requirement of the Avexitide APA and such requirement is a reasonable and appropriate condition precedent to the Purchaser's consummation of the Avexitide Sale Transaction.

FF. **Transferred Assets Property of the Estates.** The Transferred Assets constitute property of the selling Debtors' estates and title thereto is vested in the selling Debtors' estates within the meaning of section 541(a) of the Bankruptcy Code. The selling Debtors have all title, interest, and/or rights in the Transferred Assets required to transfer and to convey the Transferred Assets to the Purchaser, as required by the Avexitide APA.

GG. **Corporate Authority.** Subject to the entry of this Avexitide Sale Order, (i) the Debtors have full corporate power and authority to perform all of their obligations under the Avexitide APA and the Transaction Documents, and the Debtors' prior execution and delivery of, and performance of obligations under, the Avexitide APA and the Transaction Documents is hereby ratified, (ii) the Debtors have all of the corporate power and authority necessary to consummate the Avexitide Sale Transaction, (iii) the Debtors have taken all corporate actions necessary to authorize, approve, execute, and deliver the Avexitide APA and the Transaction Documents and to consummate the Avexitide Sale Transaction, except for the closing conditions expressly provided in the Avexitide APA and the Transaction Documents, and (iv) no consents or approvals are required to consummate the Avexitide Sale Transaction or otherwise perform the obligations under the Avexitide APA or the Transaction Documents, except for the closing conditions expressly provided herein or therein.

HH. **Sale in Best Interests.** The relief requested in the Motion and set forth in this Avexitide Sale Order is in the best interests of the Debtors, their respective creditors, estates, and all other parties in interest in the Debtors' chapter 11 cases.

II. **Prompt Consummation.** To maximize the value of the Transferred Assets, it is essential that the Avexitide Sale Transaction occur within the timeframe set forth in the Avexitide APA and Bid Procedures. Time is of the essence in consummating the Avexitide Sale

Transaction. Accordingly, there is cause to lift the stays established by Bankruptcy Rules 6004 and 6006 with regards to the Avexitide Sale Transaction and the assignment of the Assigned Contracts.

**NOW, THEREFORE, IT IS ORDERED THAT:**

1. **Motion Is Granted.** The Motion and the relief requested therein, and entry into and performance under the Avexitide APA, is GRANTED and APPROVED, as set forth herein.

2. **Objections Overruled.** Except as stated otherwise herein, all objections to, or reservation of rights regarding, the relief requested in the Motion, the entry of this Avexitide Sale Order, or the relief granted herein, including, without limitation, any objections to the assumption or assignment of the Assigned Contracts (including Cure Amounts related thereto) or relating to the cure of any defaults under any of the Designated Contracts or to the assumption and assignment of any of the Designated Contracts to the Purchaser by the Debtors, that have not been withdrawn, waived, settled, or adjourned as provided in Paragraph 18 below or otherwise, or that have not otherwise been resolved pursuant to the terms hereof are hereby denied and overruled on the merits with prejudice. All Persons that failed to timely object, or withdrew their objections, to the Motion or the entry of this Avexitide Sale Order are deemed to consent to the relief granted herein for all purposes, including, without limitation, pursuant to section 363(f)(2) of the Bankruptcy Code. No appeal, motion to reconsider, or similar pleading has been filed with respect to the Bid Procedures Order, and the Bid Procedures Order is a final order of this Court, has not been vacated, withdrawn, rescinded, or amended and remains in full force and effect.

3. **Notice.** Notice of the Motion, the Avexitide Sale Hearing, and the assumption and assignment of Assigned Contracts was adequate, appropriate, fair, and equitable under the circumstances and complied in all respects with section 102(1) of the Bankruptcy Code and

Bankruptcy Rules 2002, 6004, and 6006, the Bankruptcy Local Rules and the Bid Procedures Order, and as such no further or other notice is required.

4. **Approval and Authorization.** The sale of the Transferred Assets to the Purchaser on the terms and conditions contained in the Avexitide APA and the Transaction Documents, including, without limitation, the Closing of the Avexitide Sale Transaction as required by the Avexitide APA, is hereby approved in all respects pursuant to sections 105(a), 363(b), 363(f), 363(m), and 365 of the Bankruptcy Code and Bankruptcy Rules 6004 and 6006. Pursuant to sections 105, 363, and 365 of the Bankruptcy Code, the Debtors are authorized to perform all obligations under and make all payments required by the Avexitide APA and the Transaction Documents as and when due thereunder without further order of this Court. The Debtors, the Purchaser, and each of their respective officers, employees, and agents are hereby authorized to (i) execute the Avexitide APA and the Transaction Documents, including the Avexitide APA, and any prior execution of such agreements, documents, and instruments, including the Transaction Documents, is hereby ratified, (ii) perform all obligations under the Avexitide APA and the Transaction Documents, to consummate each of the foregoing, including, without limitation, deeds, assignments, and other instruments of transfer, and to consummate the Avexitide Sale Transaction, and any prior performance of such obligations or any prior consummation of such Avexitide Sale Transaction is hereby ratified, (iii) assume and assign the Assigned Contracts to the Purchaser, and (iv) take all other and further actions as may be reasonably necessary to consummate and implement the Avexitide Sale Transaction and to perform all obligations under the Avexitide APA and the Transaction Documents and the consummation thereof, without any further corporate action or order of this Court. The Purchaser shall not be obligated to proceed

with the Closing under the Avexitide APA until all conditions precedent to its obligation to do so thereunder have been satisfied or waived.

5. **No Sub Rosa Plan.** The sale of the Transferred Assets, including, without limitation, the assignment of the Assigned Contracts, pursuant to the Avexitide APA outside a chapter 11 plan neither impermissibly restructures the rights of the Debtors' creditors nor impermissibly dictates the terms of the Debtors' subsequent chapter 11 plan. Neither the Avexitide APA nor the Avexitide Sale Transaction constitutes a sub rosa chapter 11 plan.

6. **Valid Transfer.** As of the Closing, the consummation of the Avexitide Sale Transaction shall effect a legal, valid, and enforceable sale and transfer of the Transferred Assets to the Purchaser, and shall vest the Purchaser with all legal, equitable, and beneficial right, title, and interest in and to the Transferred Assets free and clear of all Interests of any kind or nature whatsoever. The Avexitide APA and the Transaction Documents are valid and binding contracts between the Debtors and the Purchaser and shall be enforceable pursuant to their terms. The Avexitide APA, the Transaction Documents, and the Avexitide Sale Transaction itself, and the consummation thereof, shall be specifically enforceable against and binding upon (without posting any bond) the Debtors and their respective Affiliates and subsidiaries and such parties' successors and assigns, the Debtors' estates, all creditors thereof (whether known or unknown), all holders of equity interests in any Debtor, holders of Interests in, against, or on all or any portion of the Transferred Assets, all non-Debtor parties to the Assigned Contracts, the Purchaser and its respective successors and assigns, any chapter 11 trustee appointed in these chapter 11 cases or any chapter 7 trustee appointed upon a conversion of these chapter 11 cases to cases under chapter 7 of the Bankruptcy Code, and shall not be subject to rejection or avoidance by the foregoing parties or any other Person.

7. **Free and Clear.** Except as expressly provided for in the Avexitide APA or this Avexitide Sale Order, pursuant to sections 105(a), 363(b), 363(f), 365(b), and 365(f) of the Bankruptcy Code, the Debtors are authorized and directed to transfer the Transferred Assets to the Purchaser and, upon the Closing, other than the Purchaser's assumption of the Assumed Liabilities and the Purchaser's obligations under the Avexitide APA and the Assigned Contracts, the Purchaser shall have and take title to and possession of the Transferred Assets free and clear of and shall have no obligation with respect to all Interests (other than the Assumed Liabilities) of any kind or nature whatsoever, including, without limitation, rights or claims based on any successor, transferee, derivative, or vicarious liabilities; de facto merger, continuation or continuity, or any similar theories under applicable state or federal law or otherwise. All holders of Interests fall within one or more of the subsections of section 363(f) of the Bankruptcy Code and are adequately protected by having their Interests attach to the net proceeds ultimately received by the Debtors and attributable to the Transferred Assets against or in which such Interests are asserted, subject to the terms of such Interests, with the same validity, force, and effect, and in the same order of priority that such Interests now have against the Transferred Assets or their proceeds as of Closing, subject to any rights, claims, and defenses the Debtors or their estates, as applicable, may possess with respect thereto, in addition to any limitations on the use of such proceeds pursuant to any provision of this Avexitide Sale Order. This Avexitide Sale Order: (a) is and shall be effective as a determination that, other than Assumed Liabilities or as otherwise provided herein, upon the applicable Closing in accordance with the Avexitide APA, all claims of any kind or nature whatsoever existing as to Transferred Assets, and any tax liability, prior to the applicable Closing have been unconditionally released, discharged, and terminated, and that the conveyances described herein have been effected, with such Interests and liens attaching in order of priority to



the proceeds of the Avexitide Sale Transaction, and (b) is and shall be binding upon and shall authorize all entities, including without limitation all filing agents, filing officers, title agents, title companies, recorders of mortgages, recorders of deeds, registrars of deeds, administrative agencies or units, governmental departments or units, secretaries of state, federal, state and local officials and all other persons and entities who may be required by operation of law, the duties of their office, or contract, to accept, file, register, or otherwise record or release any documents or instruments, or who may be required to report or insure any title or state of title in or to the Transferred Assets conveyed to the Purchaser. All recorded Interests against the Transferred Assets from their records, official and otherwise, shall be deemed stricken upon the Closing in accordance with the Avexitide APA and the terms of this Avexitide Sale Order without the need for further action on the part of either the Purchaser or the Seller. The conditions of section 363(f) of the Bankruptcy Code have been satisfied in full; therefore, the Debtor is authorized and directed to sell the Transferred Assets free and clear of any liens, claims, and/or interests (other than the Assumed Liabilities).

8. Those holders of Interests or claims who did not object (or who ultimately withdrew their objections, if any) to the Avexitide Sale Transaction are deemed to have consented pursuant to section 363(f)(2) of the Bankruptcy Code. Those holders of Interests or claims who did object that have an interest in the Transferred Assets fall within one or more of sections 363(f)(1), 363(f)(3), 363(f)(4), or 363(f)(5) of the Bankruptcy Code and are therefore adequately protected by having their Interests or claims that constitute interests in the Transferred Assets, if any, attach solely to the proceeds of the Avexitide Sale Transaction ultimately attributable to the property in which they have an interest, in the same order of priority and with the same validity, force, and

effect that such holders had prior to the Avexitide Sale Transaction, subject to any defenses of the Debtors.

9. As further adequate protection, the Prepetition Term Loan Agent (as defined in the Final Cash Collateral Order), on behalf of itself and the other Prepetition Term Loan Secured Parties (as defined in the Final Cash Collateral Order), shall receive at closing of the sale of the Avexitide Assets the amount of \$12 million from the sale proceeds from the sale of the Avexitide Assets (the “Adequate Protection Payment”). The Debtors, the Prepetition Term Loan Agent, and the other Prepetition Term Loan Secured Parties reserve their rights as to the allocation of the Adequate Protection Payment under the Prepetition Term Loan Credit Documents (as defined in the Final Cash Collateral Order).

10. **Release of Interests.** Any and all Persons that have filed a financing statement, mortgage, mechanic’s lien, *lis pendens*, or other document or agreement evidencing an Interest against or in the Transferred Assets shall deliver to the Debtors prior to the Closing, in proper form for filing and executed by the appropriate parties, termination statements, instruments of satisfaction, releases, and/or any other similar documents necessary for the purpose of documenting all Interests that such Person has against or in the Transferred Assets. For any Person who has not delivered such termination statements to the Debtors prior to the Closing, (i) the Debtors and/or the Purchaser are hereby authorized to execute and file such statements, instruments, releases, and/or other similar documents on behalf of such Person with respect to the Transferred Assets, (ii) the Purchaser is hereby authorized to file, register, or otherwise record a certified copy of this Avexitide Sale Order that, once filed, registered, or otherwise recorded, shall constitute conclusive evidence of the release of all Interests of any kind or nature against or in the Transferred Assets, and (iii) the Purchaser may seek in this Court, or any other court of appropriate

jurisdiction, to compel the appropriate parties to execute termination statements, instruments of satisfaction, releases, and/or other similar documents with respect to all Interests that such Person has against or in the Transferred Assets. This Avexitide Sale Order is deemed to be in recordable form sufficient to be placed in the filing or recording system of each and every federal, state, or local government agency, department, or office. Notwithstanding the foregoing, the provisions of this Avexitide Sale Order authorizing the sale and assignment of the Transferred Assets free and clear of all Interests shall be self-executing, and neither the Debtors nor the Purchaser shall be required to execute or file releases, termination statements, assignments, consents, or other instruments in order to effectuate, consummate, and implement the provisions of this Avexitide Sale Order.

11. **Surrender of Transferred Assets.** All Persons that are presently or on the Closing Date may be in possession of some or all of the Transferred Assets are directed to surrender possession of such Transferred Assets to the Purchaser as of the Closing Date.

12. **Continuation of Existing Approvals.** The Purchaser shall be authorized, as of the Closing Date, to operate under any license, permit, registration, and governmental authorization or approval of the Debtors with respect to the Transferred Assets (subject, in each case, to the terms of the Avexitide APA), and all such licenses, permits, registrations, and governmental authorizations or any other approvals are deemed to have been, and hereby are, directed to be transferred to the Purchaser as of the Closing Date. All existing licenses or permits applicable to the business shall remain active, in place, and, as applicable, shall be renewed for the Purchaser's benefit until either new licenses and permits are obtained or existing licenses and permits are transferred in accordance with applicable administrative procedures. To the maximum extent permitted by section 525(a) of the Bankruptcy Code, no governmental unit (as defined in

Bankruptcy Code § 101(27)) or any representative thereof may revoke or suspend, or in any way challenge or fail to consent to any renewal of any permit or license relating to the operation of the Transferred Assets because of the filing or pendency of the Debtors' chapter 11 cases or the consummation of the Avexitide Sale Transaction.

13. **Injunction.** All Persons are hereby prohibited and enjoined from taking any action that would adversely affect or interfere with, or that would be inconsistent with, the ability of the Debtors to sell and transfer the Transferred Assets to the Purchaser in accordance with the terms of the Avexitide APA, the Transaction Documents, or this Avexitide Sale Order. Except as expressly permitted by the Avexitide APA with respect to Assumed Liabilities or this Avexitide Sale Order, all Persons (and their respective successors and assigns), including, without limitation, all holders of claims or Interests, lenders, debt security holders, governmental, tax and regulatory authorities, parties to executory contracts and unexpired leases, creditors, contract counterparties, customers, landlords, licensors, employees and former employees, litigation claimants, pension plans, labor unions, trade creditors, and other Persons holding Interests of any kind or nature whatsoever against or in the Debtors or the Transferred Assets (whether known or unknown, legal or equitable, matured or unmatured, contingent or non-contingent, liquidated or unliquidated, asserted or unasserted, whether arising prior to or subsequent to the commencement of the Debtors' chapter 11 cases, whether imposed by agreement, understanding, law, equity, or otherwise), arising under or out of, in connection with, or in any way relating to, the Debtors, the operation of the Debtors' businesses prior to the Closing, the Transferred Assets, or the transfer of the Transferred Assets to the Purchaser (including, without limitation, any rights or claims based on any successor, transferee, derivative, or vicarious liabilities), shall be and hereby are forever barred, estopped, and permanently enjoined from asserting, prosecuting, or otherwise pursuing any Interests against

the Purchaser, any of its Affiliates, officers, directors, members, partners, principals, or shareholders, any of their respective representatives, successors, designees, or assigns, the property of the foregoing, and the Transferred Assets transferred to the Purchaser or interests of the Debtors in such Transferred Assets (other than the Assumed Liabilities). Following the Closing, no holder of an Interest against the Debtors shall interfere with the Purchaser's title to or use and enjoyment of the Debtors' former interests in the Transferred Assets, including, without limitation, taking any of the following actions with respect to or based on any Interest relating to the Transferred Assets or the transfer of the Transferred Assets to the Purchaser (other than Assumed Liabilities): (a) commencing or continuing in any manner any action or other proceeding against the Purchaser or its successors or assigns, assets or properties; (b) enforcing, attaching, collecting, or recovering in any manner any judgment, award, decree, or order against the Purchaser or its successors or assigns, assets, or properties; (c) creating, perfecting, or enforcing any Interest against the Purchaser, its successors or assigns, assets (including the Transferred Assets), or properties; (d) asserting any Interest as a setoff, right of subrogation, or recoupment of any kind against any obligation due Purchaser or its successors or assigns; (e) commencing or continuing any action in any manner or place that does not comply or is inconsistent with the provisions of this Avexitide Sale Order or the agreements or actions contemplated or taken in respect thereof; (f) interfering with, preventing, restricting, prohibiting, or otherwise enjoining the consummation of the Sale Transactions; or (g) enforcing any provision of any Assigned Contract that prohibits, restricts or conditions, or which purports to terminate or modify, or permits a party other than the Debtors to terminate or modify, any such Assigned Contract, or any right or obligation under such Assigned Contract, because of the assumption and assignment of such Assigned Contract by the Debtors to the Purchaser. For the avoidance of doubt, and without limiting the generality of the foregoing or

the operability of any other relief obtained pursuant to this Avexitide Sale Order, any provision in an Assigned Contract, any other document, or any applicable law that purports to prohibit, restrict, modify or otherwise impair assignment of the Assigned Contracts or the Purchaser's ability to utilize the Transferred Assets in Purchaser's business is hereby void and of no force and effect with respect to the Avexitide Sale Transaction, including without limitation any provision that (a) terminates or modifies any right or obligation of the Purchaser under such Assigned Contract; (b) cross-defaults to or from any other lease or executory contract that is not an Assigned Contract; (c) contains operating covenants or "go-dark" provisions that would purport to terminate or modify any Assigned Contract before assumption and assignment to the Purchaser; (d) requires a third party's consent prior to assignment of the Assigned Contract to the Purchaser; or (e) restricts the Purchaser's use or assignment of any licenses or similar permits if transferred.

14. **General Assignment.** As of the Closing, this Avexitide Sale Order shall be construed and shall constitute for any and all purposes a full and complete general assignment, conveyance, and transfer of the Transferred Assets and/or a bill of sale or assignment transferring indefeasible title and interest in the Transferred Assets, including the Assigned Contracts, to the Purchaser. Each and every federal, state, and local governmental agency or department is hereby authorized and directed to accept any and all documents and instruments necessary and appropriate to consummate the Avexitide Sale Transaction and to reflect the effectiveness of the Avexitide Sale Transaction.

15. **No Successor, Transferee, or Similar Liability.** The Purchaser, its Affiliates, and any of their respective officers, directors, members, partners, principals, employees, independent contractors, and shareholders (or equivalent) and any of their respective representatives, agents, predecessors, successors, or assigns shall not be and shall not be deemed, as a result of the

consummation of the Avexitide Sale Transaction or otherwise, (i) to be a successor of, successor employer of, successor entity of, to have successorship obligations relating to, or to otherwise be deemed a successor, to the Debtors or the Debtors' estates, including with respect to any labor, employment, employee, personnel, or worker related matter, law, or agreement, including any collective bargaining agreement, works council agreement, union agreement, area labor agreement, multiemployer agreement, project labor agreement, construction agreement, contractor agreement, building agreement, regional agreement, work standards agreement, or other labor Contract (collectively, a "Collective Bargaining Agreement"), any employee benefit plans, any defined benefit pension plan, or any multiemployer plans, and the Purchaser and/or its Affiliates, as applicable, shall instead be, and be deemed to be, a new employer, including with respect to, among other things, any and all federal or state unemployment laws, including the Fair Labor Standards Act, any employee wage and hour law, privacy law, worker classification law, minimum wage law, overtime law, compensation or benefit law, meal or rest break law, time keeping law, employee record or documentation law, workers compensation law, unemployment compensation or tax law, or any other similar federal or state law (provided that the Purchaser shall pay employee-related liabilities solely to the extent expressly included in the Assumed Liabilities); (ii) to have any common law successorship liability in relation to any Collective Bargaining Agreement, union, multiemployer organization, employee benefit plan, or multiemployer plan, including with respect to withdrawal liability or contribution obligations; (iii) to have, de facto or otherwise, merged or consolidated with or into any of the Debtors or any of the Debtors' estates, (iv) to be the successor of or a successor employer (as defined under COBRA and applicable regulations thereunder, common law, or otherwise) to the Debtors; (v) to have a common identity with the Debtors; (vi) to be an alter ego, joint employer, single employer, a continuation or

substantial continuation, or to be holding itself out as a mere continuation, of any of the Debtors or their respective estates, or any enterprise of any of the Debtors, (vii) to be liable for any acts or omissions of the Seller or any of the other Debtors in connection with any Collective Bargaining Agreement, personnel, worker, employee, independent contractor, the conduct of the business, or the operation, funding, or administration of the employee benefit plans or multiemployer plans or arising under or related to the Transferred Assets other than as expressly set forth in the Avexitide APA; (viii) to have any successor liability, transferee liability, derivative liability, vicarious liability, or any similar theories of any kind or character including, without limitation, under any theory of foreign, federal, state, or local antitrust, environmental, successor, tax, ERISA, assignee or transferee liability, labor, product liability, employment, de facto merger, substantial continuity, or other law, rule, regulation, or doctrine, whether known or unknown as of the Closing Date, whether now existing or hereafter arising, whether asserted or unasserted, fixed or contingent, liquidated or unliquidated; (ix) except as expressly set forth in the Avexitide APA, to have any successor liability, transferee liability, derivative, liability, vicarious liability, for any similar theories of any kind or character including under any pending, threatened, or potential claim, litigation, arbitration, settlement, investigation, fact circumstance, or event disclosed in the Transaction Documents; in each case whether known or unknown as of the Closing Date, whether now existing or hereafter arising, whether asserted or unasserted, fixed or contingent, liquidated or unliquidated, except to the extent solely and expressly provided for in the Avexitide APA. The Purchaser shall not assume, or be deemed to assume, or in any way be responsible for any liability or obligation of any of the Debtors and/or their respective estates, or any of their predecessors or Affiliates. The so-called “bulk sales,” “bulk transfer,” or other similar laws shall be waived in all necessary jurisdictions, including those relating to Taxes. Except as expressly set forth in the



Avexitide APA with respect to Assumed Liabilities, the Purchaser, its Affiliates, officers, directors, members, partners, principals, and shareholders (or equivalent) and any of their respective representatives, successors, or assigns, or the Transferred Assets shall have no liability or responsibility whatsoever with respect to, or be required to satisfy in any manner, whether at law or in equity, whether by payment, setoff or otherwise, directly or indirectly (w) any Interest against the Debtors or against an insider of the Debtors, (x) any Interest or Excluded Liabilities, (y) the Debtors except as expressly set forth in the Avexitide APA and the Transaction Documents.

16. **Good Faith of the Purchaser.** The Avexitide Sale Transaction specified in the Avexitide APA is undertaken by the Purchaser without collusion and in good faith, as that term is defined in section 363(m) of the Bankruptcy Code, and, accordingly, the reversal or modification on appeal of the authorization provided herein to consummate the sale shall not affect the validity of the Avexitide Sale Transaction, including, without limitation, the assumption and assignment of the Assigned Contracts, unless such authorization and consummation of the sale are duly and properly stayed pending such appeal. The Purchaser is a good faith purchaser within the meaning of section 363(m) of the Bankruptcy Code and, as such, is entitled to the full protections of section 363(m) of the Bankruptcy Code.

17. **No Avoidance of the Avexitide APA.** Neither the Debtors nor the Purchaser have engaged in any conduct that would cause or permit the Avexitide APA to be avoided or costs and damages to be imposed under section 363(n) of the Bankruptcy Code. Accordingly, the Avexitide APA and the Avexitide Sale Transaction shall not be avoidable under section 363(n) of the Bankruptcy Code, and no party shall be entitled to any damages or other recovery pursuant to section 363(n) of the Bankruptcy Code in respect of the Avexitide APA or the Avexitide Sale

Transaction. Specifically, the Purchaser has not acted in a collusive manner with any person or entity and the Avexitide Purchase Price was not controlled by any agreement among bidders.

18. **Cure and Cure Dispute Resolution.** All defaults or other obligations of the Debtors under the Designated Contracts arising prior to the Closing (without giving effect to any acceleration clauses or any default provisions of the kind specified in section 365(b)(2) of the Bankruptcy Code) as to which no objections were interposed and remain pending as of the date of this Avexitide Sale Order are deemed satisfied by the payment of the proposed amount necessary, if any, to cure all monetary defaults, if any, under such Designated Contract in those amounts set forth in the Assignment Notice, which was served in compliance with the Bid Procedures Order, and which were satisfied, or shall be satisfied as soon as practicable. For all Designated Contracts for which an Assignment Notice was served, the Purchaser is authorized and directed to pay all Cure Amounts required to be paid by such parties upon the later of (a) the Closing, or (b) for any Designated Contract for which an objection has been filed to the assumption and assignment of such agreement or the Cure Amounts relating thereto and such objection remains pending as of the date of this Avexitide Sale Order (a “Cure Dispute”), within ten (10) business days of the resolution of such objection by settlement or order of this Court. Any non-Debtor counterparty to a Designated Contract that has not filed an objection on or before the deadline as set forth in the relevant Assignment Notice, or received an informal extension by the Debtors, shall be barred from objecting or asserting monetary or non-monetary defaults with respect to any such Designated Contract other than the applicable amount set forth in the Assignment Notice, and such Designated Contract shall be deemed assumed by the Debtors and assigned to the Purchaser on the Closing Date. To the extent that any Cure Dispute cannot be consensually resolved by the applicable parties, whether before or after the Closing Date, such Designated Contracts shall be

assumed and assigned only upon satisfactory resolution of the Cure Dispute, to be determined in the Purchaser's reasonable discretion. To the extent a Cure Dispute exists, the Designated Contracts may be conditionally assumed and assigned, subject to the consent of the Purchaser, pending a resolution of the Cure Dispute by agreement of the parties or after notice and a hearing. If a Cure Dispute is not satisfactorily resolved, the Purchaser may determine that such Designated Contracts should not be included on their schedule of Designated Contracts and should be rejected and not assigned, in which case the Purchaser will not be responsible for any Cure Amounts to the contract counterparty. The Debtors may then seek to reject the applicable contract or lease pursuant to Section 365 of the Bankruptcy Code.

19. **Determination of Cure Amounts.** Unless a counterparty to any Designated Contract has filed a timely Cure Objection which remains subject to an unresolved Cure Dispute as of the entry of this Avexitide Sale Order, the Cure Amounts set forth on the Assignment Notices shall constitute findings of this Court and shall be final and binding on the counterparties to the Designated Contracts and their successors and designees upon the Closing and shall not be subject to further dispute or audit based on performance prior to the time of assumption and assignment, irrespective of the terms and conditions of such Designated Contracts. Each counterparty to a Designated Contract (other than a counterparty who filed a timely Cure Objection) shall be forever barred, estopped, and permanently enjoined from (i) asserting against the Purchaser or its property (including, without limitation, the Transferred Assets), any default arising prior to or existing as of the Closing, or any counterclaim, defense, recoupment, setoff, or any other Interest asserted or assertable against the Debtors (except as otherwise provided herein), and (ii) imposing or charging against the Purchaser or its Affiliates, any accelerations, assignment fees, increases, or any other fees or charges as a result of the Debtors' assumption and assignment to the Purchaser of the

Designated Contracts in connection with the Avexitide Sale Transaction approved by this Avexitide Sale Order. To the extent a counterparty to any of the Designated Contracts received notice of the Debtors' proposed Cure Amount and fails to file a Cure Objection by the applicable deadline, such party shall be deemed to have (a) consented to the assumption and assignment of the applicable Designated Contract and the payment of the Cure Amount provided in the Assignment Notices and (b) waived any right to assert or collect any other cure amount or enforce any default that may arise or have arisen prior to or as of the Closing.

20. **Payment of Cure Amounts.** With respect to the Assigned Contracts, to the extent there are any Cure Amounts unpaid as of the Closing Date, the Purchaser shall be obligated, and is hereby directed, to pay or cause to be paid such Cure Amounts, unless a Cure Amount is subject to an unresolved Cure Dispute, in which case the Purchaser shall pay the Cure Amount in accordance with Paragraph 18 above, or unless the Debtors are otherwise required under applicable law to make such payments prior to the Closing, in which case the Debtors shall obtain both the Prepetition Term Loan Administrative Agent's (as defined in the Final Cash Collateral Order) and the Purchaser's written consent before making such payments and Purchaser shall reimburse the Debtors for such amounts paid by the Debtors, provided that the Purchaser shall receive a credit to the Purchase Price for any such Cure Amounts. The Purchaser's promise to perform the obligations under the Designated Contracts arising after their assumption and assignment to the Purchaser shall constitute adequate assurance of future performance within the meaning of sections 365(b) and 365(f)(2) of the Bankruptcy Code. On the Closing Date, subject in all respects to the terms of this Avexitide Sale Order, the Purchaser shall be deemed to be substituted for the Seller (and/or any other Debtor, to the extent any of them hold any rights, title, or interests in any of the Designated Contracts) as a party to the applicable Designated Contracts.

21. **Ipsso Facto Clauses Ineffective.** Upon the Debtors' assumption and assignment of the Designated Contracts to the Purchaser pursuant to this Avexitide Sale Order and the payment of the Cure Amounts in accordance with this Avexitide Sale Order and the Avexitide APA, no default shall exist under any Designated Contract and no counterparty to any such Designated Contract shall be permitted to declare or enforce a default by the Debtors or the Purchaser thereunder or otherwise take action against the Purchaser as a result of any Debtor's financial condition, change in control, bankruptcy, or failure to perform any of its obligations under the applicable Designated Contract. For the avoidance of doubt, and without limiting the generality of the foregoing or the operability of any other relief obtained pursuant to this Avexitide Sale Order, any provision in a Designated Contract that prohibits or conditions, whether directly or indirectly, the assignment of such Designated Contract (including, without limitation, the granting of an Interest therein) or allows the counterparty thereto to terminate, recapture, impose any penalty, condition on renewal or extension, or modify any term or condition upon such assignment shall be deemed an unenforceable anti-assignment provision that is void and of no force and effect with respect to the Avexitide Sale Transaction as approved by this Avexitide Sale Order. The failure of the Debtors or the Purchaser to enforce at any time one or more terms or conditions of any Designated Contract shall not be a waiver of such terms or conditions or of the Debtors' or the Purchaser's right, as applicable, to enforce every term and condition of such Designated Contract.

22. **Binding Effect.** This Avexitide Sale Order and the Avexitide APA shall be binding upon and shall govern the acts of all entities, including, without limitation, all filing agents, filing officers, title agents, title companies, recorders of mortgages, recorders of deeds, registrars of deeds, administrative agencies, governmental departments, secretaries of state, federal, state and local officials, and all other Persons who may be required by operation of law, the duties of their

office, or contract, to accept, file, register, or otherwise record or release any documents or instruments, or who may be required to report or insure any title or state of title in or to any of the Transferred Assets. The terms and provisions of the Avexitide APA, the Transaction Documents, the Bid Procedures Order, and this Avexitide Sale Order shall be binding in all respects upon the Debtors and their respective Affiliates and subsidiaries and such parties' successors and assigns, the Debtors' estates, all creditors thereof (whether known or unknown), all holders of equity interests in any Debtor, holders of Interests in, against, or on all or any portion of the Transferred Assets, all non-Debtor parties to the Designated Contracts, the Purchaser and its respective successors and assigns, and any and all third parties, notwithstanding any subsequent appointment of any trustee, examiners, "responsible persons" or other fiduciaries (collectively, the "Trustee") of the Debtors under any chapter of the Bankruptcy Code, as to which Trustee such terms and provisions likewise shall be binding, and the Avexitide APA (including the Assigned Contracts) shall not be subject to rejection or avoidance under any circumstances.

23. **Release, Discharge, and Termination of Interests.** This Avexitide Sale Order shall be effective as a determination that, on the Closing, all Interests of any kind or nature whatsoever existing prior to the Closing have been unconditionally released, discharged, and terminated solely as to the Transferred Assets (other than the Assumed Liabilities), and that the conveyances described herein have been effected.

24. **No Material Modifications.** The Avexitide APA and the Transaction Documents may be modified, amended, or supplemented by the Debtors and the Purchaser, in a writing signed by such parties, and in accordance with the terms thereof, without further order of this Court; *provided*, that (i) any such modification, amendment, or supplement does not have a material adverse effect on the Debtors' estates or its creditors, and (ii) has been agreed to between the Seller

and the Purchaser (with respect to the Seller, such consent not to be unreasonably withheld) and approved by the Prepetition Term Loan Administrative Agent. Any material modification, amendment, or supplement to the Avexitide APA and the Transaction Documents adversely affecting the Debtors' estates must be filed on the docket and served on all interested parties. Interested parties shall have five business days to file an objection to any such material modification, amendment, or supplement. If no objections are received within five business days or the Court overrules such filed objections, the modified Avexitide APA and Transaction Documents shall be effective.

25. **Subsequent Orders and Plan Provisions.** Nothing contained in any chapter 11 plan confirmed in the Debtors' chapter 11 cases or any subsequent order of this Court, including, without limitation, any order confirming any such chapter 11 plan, any order authorizing the sale of assets of the Debtors pursuant to any section of the Bankruptcy Code, and any order approving wind-down or dismissal of any Debtor's chapter 11 case or any subsequent chapter 7 case shall change, supersede, abrogate, nullify, restrict, or conflict with the provisions of the Avexitide APA, the Transaction Documents, or this Avexitide Sale Order, or in any way prevent or interfere with the consummation or performance of the Avexitide Sale Transaction.

26. **Failure to Specify Provisions.** The failure to specify or include any particular provisions of the Avexitide APA or the Transaction Documents in this Avexitide Sale Order shall not diminish or impair the effectiveness of such provisions, it being the intent of this Court that the Avexitide APA, the Transaction Documents, and the Avexitide Sale Transaction be authorized and approved in their entirety.

27. **Automatic Stay.** The automatic stay pursuant to section 362 of the Bankruptcy Code is hereby lifted solely to the extent necessary to (i) allow the Purchaser to deliver

any notice provided for in the Avexitide APA and the Transaction Documents, and (ii) allow the Purchaser to take any and all actions permitted under the Avexitide APA and the Transaction Documents in accordance with the terms and conditions thereof. The automatic stay imposed by section 362 of the Bankruptcy Code shall be modified solely to the extent necessary to implement the preceding sentence, and this Court shall retain exclusive jurisdiction over any and all disputes with respect thereto.

28. **Bankruptcy Rules Satisfied or Waived.** The requirements set forth in Bankruptcy Rules 6004 and 6006 have been satisfied or are otherwise deemed to be waived. As provided by Bankruptcy Rule 9014, the terms of this Avexitide Sale Order shall be effective and enforceable immediately upon entry and shall not be subject to stay provisions contained in Bankruptcy Rules 6004(h) and 6004(d). Time is of the essence in closing the Avexitide Sale Transaction and the Debtors and the Purchaser intend to close the sale as soon as possible.

29. **Conflicts Between Sale Order and Avexitide APA.** To the extent anything contained in this Avexitide Sale Order conflicts with a provision in the Avexitide APA or Transaction Documents, this Avexitide Sale Order shall govern and control. Notwithstanding the foregoing, nothing in this Avexitide Sale Order shall modify or waive any closing conditions or termination rights in the Avexitide APA, and all such conditions and rights shall remain in full force and effect in accordance with their terms.

30. **Provisions Nonseverable and Mutually Dependent.** The provisions of this Avexitide Sale Order, the Avexitide APA, and the Transaction Documents are non-severable and mutually dependent.

31. **Retention of Jurisdiction.** This Court shall retain exclusive jurisdiction to, among other things, interpret, implement, and enforce the terms and provisions of the Avexitide APA, the



Transaction Documents, the Bid Procedures Order, and this Avexitide Sale Order, and each of the agreements executed in connection therewith to which the Debtors are a party or which has been assigned to the Purchaser by the Debtors, and to adjudicate, if necessary, any and all disputes concerning or relating in any way to the Avexitide Sale Transaction. This Court retains jurisdiction to compel delivery of the Transferred Assets, to protect the Purchaser and its assets, including the Transferred Assets, against any Interests or successor or transferee liability and to enter orders, as appropriate, pursuant to sections 105(a), 363, or 365 (or other applicable sections) of the Bankruptcy Code necessary to transfer the Transferred Assets and the Designated Contracts to the Purchaser. In the event this Court abstains from exercising or declines to exercise jurisdiction with respect to any matter referenced in this paragraph or is without jurisdiction, such abstention, refusal, or lack of jurisdiction shall have no effect upon and shall not control, prohibit, or limit the exercise of jurisdiction of any other court having competent jurisdiction with respect to any such matter.

32. The Purchaser has standing to seek to enforce any terms of this Avexitide Sale Order, the Bid Procedures Order, the Avexitide APA, and the Transaction Documents in this Court or any other court with competent jurisdiction.

33. All time periods set forth in this Avexitide Sale Order shall be calculated in accordance with Bankruptcy Rule 9006(a).

Submitted By:

**SIDLEY AUSTIN LLP**

Thomas Califano (TX Bar No. 24122825)

William Curtin (admitted *pro hac vice*)

Anne Wallice (admitted *pro hac vice*)

787 Seventh Avenue

New York, NY 10019

Telephone: (212) 839-5300

Facsimile: (212) 839-5599

Email: tom.califano@sidley.com

wcurtin@sidley.com

anne.wallice@sidley.com

Charles Persons (TX Bar No. 24060413)

2021 McKinney Avenue, Suite 2000

Dallas, Texas 75201

Telephone: (214) 981-3300

Facsimile: (214) 981-3400

Email: cpersons@sidley.com

*Attorneys for the Debtors and Debtors in  
Possession*